Abstract
To the Editor:
Xie et al’s 1 recent network meta-analysis in Integrative Cancer Therapies compared multiple acupuncture modalities for cancer-related pain and concluded that several approaches may yield benefit with acceptable safety. Their work contributes to ICT’s expanding acupuncture literature and marks progress toward integrative oncology recommendations. However, if acupuncture evidence is to inform clinical and policy decisions, methodological tightening is essential.
First, the transitivity assumption in network meta-analysis deserves careful safeguarding. Variability across acupuncture modalities (body, electro, auricular), session dose/frequency, concurrent analgesics, and co-therapies can threaten transitivity and yield unstable ranking of interventions. As recent methodological reviews emphasize, authors should predefine effect modifiers (eg, treatment dose, baseline pain severity, opioid use), set thresholds for imbalance, and downgrade confidence when violations emerge.2,3
Second, many “sham” acupuncture comparators are not physiologically inert, potentially diluting true effects. Since ICT has recently published work on expectancy/placebo–nocebo dynamics in integrative therapies, 4 authors should consider favoring pragmatic comparative-effectiveness designs (eg, acupuncture + standard care vs standard care alone) when sham credibility is doubtful. Where sham is used, reporting of blinding credibility, expectancy calibration, and treating sham modality as an effect modifier in NMAs is critical.2,3
Third, harmonization of outcomes and clinical meaning is vital. Trials and meta-analyses should adopt core endpoints aligned with oncology guidelines (pain intensity/interference, opioid sparing, quality of life) and explicitly define minimally important differences (MIDs). This allows interpretation in terms of probability of achieving clinically meaningful effects, not only statistical significance.2,3
Finally, to enhance global relevance, accessibility must be built into innovation pipelines. Self-acupressure apps, task-sharing models, and pragmatic/adaptive trials combining acupuncture with other nonpharmacologic therapies can widen reach beyond high-resource centers. 5 Planning trials that emphasize cost per responder, time-to-access, and equity metrics will increase policy uptake.
ICT is well positioned to catalyze methodological consensus: a checklist for acupuncture NMAs, reporting of comparator credibility, uniform symptom/biomarker sets, and equity-minded trial metrics could be endorsed as a field standard. These moves would amplify the translational and global impact of acupuncture research in integrative oncology.
